These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25964969)

  • 21. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study.
    Inoue Y; Shimizu T; Hirata K; Uchimura N; Ishigooka J; Oka Y; Ikeda J; Tomida T; Hattori N;
    Sleep Med; 2013 Nov; 14(11):1085-91. PubMed ID: 24055212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rotigotine transdermal delivery for the treatment of restless legs syndrome.
    Sixel-Döring F; Trenkwalder C
    Expert Opin Pharmacother; 2010 Mar; 11(4):649-56. PubMed ID: 20163275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rotigotine: the first new chemical entity for transdermal drug delivery.
    McAfee DA; Hadgraft J; Lane ME
    Eur J Pharm Biopharm; 2014 Nov; 88(3):586-93. PubMed ID: 25173087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT.
    Bauer A; Cassel W; Benes H; Kesper K; Rye D; Sica D; Winkelman JW; Bauer L; Grieger F; Joeres L; Moran K; Schollmayer E; Whitesides J; Carney HC; Walters AS; Oertel W; Trenkwalder C;
    Neurology; 2016 May; 86(19):1785-93. PubMed ID: 27164714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience.
    Raeder V; Boura I; Leta V; Jenner P; Reichmann H; Trenkwalder C; Klingelhoefer L; Chaudhuri KR
    CNS Drugs; 2021 Feb; 35(2):215-231. PubMed ID: 33559846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome.
    Ferini-Strambi L; Marelli S; Galbiati A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):967-75. PubMed ID: 27224246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug safety evaluation of rotigotine.
    Sprenger FS; Seppi K; Poewe W
    Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Another dopamine agonist for treatment of restless legs syndrome.
    Earley CJ
    Lancet Neurol; 2011 Aug; 10(8):675-7. PubMed ID: 21705274
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pharmacology sheet. Transdermal Rotigotine (Neupro)].
    J Pharm Belg; 2010 Jun; (2):49-50. PubMed ID: 20623986
    [No Abstract]   [Full Text] [Related]  

  • 30. Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective.
    Chung SJ; Asgharnejad M; Bauer L; Benitez A; Boroojerdi B; Heidbrede T; Little A; Kim HJ
    Expert Rev Neurother; 2017 Jul; 17(7):737-749. PubMed ID: 28548894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allergic contact dermatitis caused by rotigotine in a transdermal therapeutic system.
    Raison-Peyron N; Guillot B
    Contact Dermatitis; 2016 Aug; 75(2):121-2. PubMed ID: 27385523
    [No Abstract]   [Full Text] [Related]  

  • 32. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
    Zareba G
    Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.
    Cawello W; Kim SR; Braun M; Elshoff JP; Ikeda J; Funaki T
    Clin Drug Investig; 2014 Feb; 34(2):95-105. PubMed ID: 24178238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contact leukoderma induced by rotigotine transdermal patch (Neupro®).
    Takeuchi A; Egawa G; Nomura T; Kabashima K
    Eur J Dermatol; 2019 Apr; 29(2):215-217. PubMed ID: 30734716
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease).
    Elshoff JP; Hudson J; Picchietti DL; Ridel K; Walters AS; Doggett K; Moran K; Oortgiesen M; Ramirez F; Schollmayer E
    Sleep Med; 2017 Apr; 32():48-55. PubMed ID: 28366342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, safety, and tolerability of rotigotine transdermal system in healthy Japanese and Caucasian subjects following multiple-dose administration.
    Cawello W; Kim SR; Braun M; Elshoff JP; Masahiro T; Ikeda J; Funaki T
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):353-62. PubMed ID: 25773763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of restless legs syndrome with rotigotine.
    García-Borreguero D; Oertel W; Trenkwalder C;
    Lancet Neurol; 2011 Oct; 10(10):872-3. PubMed ID: 21939896
    [No Abstract]   [Full Text] [Related]  

  • 39. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
    Winkelman JW; Mackie SE; Mei LA; Platt S; Schoerning L
    Sleep Med; 2016 Aug; 24():18-23. PubMed ID: 27810181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial.
    Trenkwalder C; Benes H; Poewe W; Oertel WH; Garcia-Borreguero D; de Weerd AW; Ferini-Strambi L; Montagna P; Odin P; Stiasny-Kolster K; Högl B; Chaudhuri KR; Partinen M; Schollmayer E; Kohnen R;
    Lancet Neurol; 2008 Jul; 7(7):595-604. PubMed ID: 18515185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.